JP2021521243A5 - - Google Patents

Info

Publication number
JP2021521243A5
JP2021521243A5 JP2020558021A JP2020558021A JP2021521243A5 JP 2021521243 A5 JP2021521243 A5 JP 2021521243A5 JP 2020558021 A JP2020558021 A JP 2020558021A JP 2020558021 A JP2020558021 A JP 2020558021A JP 2021521243 A5 JP2021521243 A5 JP 2021521243A5
Authority
JP
Japan
Prior art keywords
compound according
alkyl
cancer
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020558021A
Other languages
English (en)
Japanese (ja)
Other versions
JP7411315B2 (ja
JP2021521243A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028135 external-priority patent/WO2019204614A1/en
Publication of JP2021521243A publication Critical patent/JP2021521243A/ja
Publication of JP2021521243A5 publication Critical patent/JP2021521243A5/ja
Application granted granted Critical
Publication of JP7411315B2 publication Critical patent/JP7411315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020558021A 2018-04-19 2019-04-18 Ｓｔａｔ３阻害剤 Active JP7411315B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659872P 2018-04-19 2018-04-19
US62/659,872 2018-04-19
US201962793491P 2019-01-17 2019-01-17
US62/793,491 2019-01-17
PCT/US2019/028135 WO2019204614A1 (en) 2018-04-19 2019-04-18 Stat3 inhibitors

Publications (3)

Publication Number Publication Date
JP2021521243A JP2021521243A (ja) 2021-08-26
JP2021521243A5 true JP2021521243A5 (https=) 2022-04-22
JP7411315B2 JP7411315B2 (ja) 2024-01-11

Family

ID=68240338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558021A Active JP7411315B2 (ja) 2018-04-19 2019-04-18 Ｓｔａｔ３阻害剤

Country Status (18)

Country Link
US (2) US11826315B2 (https=)
EP (2) EP3773537B1 (https=)
JP (1) JP7411315B2 (https=)
KR (1) KR102792113B1 (https=)
CN (1) CN112367984B (https=)
AU (1) AU2019255755B2 (https=)
BR (1) BR112020021329A2 (https=)
DK (1) DK3773537T3 (https=)
ES (1) ES2911428T3 (https=)
HU (1) HUE059318T2 (https=)
IL (1) IL278112B2 (https=)
MX (1) MX2020011065A (https=)
MY (1) MY207195A (https=)
PH (1) PH12020551728A1 (https=)
PL (1) PL3773537T3 (https=)
PT (1) PT3773537T (https=)
SG (1) SG11202010347XA (https=)
WO (1) WO2019204614A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
CN114761405A (zh) * 2019-11-29 2022-07-15 南京明德新药研发有限公司 抗hbv的1,7-萘啶类化合物
JP2023504194A (ja) * 2019-12-03 2023-02-01 ベイラー カレッジ オブ メディスン インスリン耐性における使用方法のための治療化合物
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
AR128676A1 (es) * 2022-03-01 2024-06-05 Tvardi Therapeutics Inc Compuestos terapéuticos, formulaciones, uso y método de preparación
US20250170079A1 (en) * 2022-03-04 2025-05-29 Tvardi Therapeutics, Inc. Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer
CA3254067A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. STAT3 INHIBITOR MEDICINES
TW202412749A (zh) * 2022-07-21 2024-04-01 美商特梵迪治療股份有限公司 治療性化合物、調配物、及其用途
EP4633620A1 (en) * 2022-12-12 2025-10-22 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of non-viral liver cancer
WO2025184497A1 (en) * 2024-02-29 2025-09-04 Tvardi Therapeutics, Inc. Stat3 inhibitors for use in the treatment of cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4279909A (en) 1980-02-13 1981-07-21 Fujisawa Pharmaceutical Co., Ltd. Antiallergic method
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US6197749B1 (en) 1997-10-29 2001-03-06 Ajinomoto Co., Inc. Method of suppressing immune responses by reducing intracellular content of glutathione in macrophages and monocytes
CA2413878A1 (en) 2000-06-20 2001-12-27 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
WO2005026134A1 (en) 2003-09-17 2005-03-24 Novartis Ag Organic compounds
US20050287664A1 (en) 2004-05-27 2005-12-29 Ming-Ji Fann Cellular proliferation control factors
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
US20100035793A1 (en) 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
CA2636909A1 (en) 2006-01-13 2007-07-26 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production with tanshinones
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
US20090264353A1 (en) 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2009038784A1 (en) 2007-09-21 2009-03-26 Amgen Inc. Triazole fused heteroaryl compounds as p38 kinase inhibitors
EP2299999B1 (en) * 2008-06-04 2017-08-16 Baylor College Of Medicine Stat3 inhibitors
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
WO2010080581A2 (en) 2008-12-19 2010-07-15 The Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Valproic acid, derivatives, analogues, and compositions including same and methods for their therapeutic use
US8557805B2 (en) 2008-12-29 2013-10-15 Takeda Pharmaceutical Company Limited Fused ring compound and use thereof
US9891213B2 (en) 2009-01-12 2018-02-13 The Board Of Trustees Of The Leland Stanford Junior University Granulocyte-based methods for detecting and monitoring immune system disorders
CA2781706A1 (en) * 2009-11-24 2011-06-03 The Ohio State University Transcription factor inhibitors and related compositions, formulations and methods
FR2962649B1 (fr) 2010-07-19 2025-10-24 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20140371188A1 (en) 2011-11-23 2014-12-18 University Of Iowa Research Foundation Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
CN102766103B (zh) * 2012-07-24 2014-12-10 齐鲁制药有限公司 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
AU2014290363B2 (en) * 2013-07-18 2019-02-21 Baylor College Of Medicine Methods and compositions for treatment of fibrosis
AU2014290368B2 (en) 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
US20150031714A1 (en) 2013-07-18 2015-01-29 Baylor College Of Medicine Methods and compositions for prevention of allergic reaction
WO2017083719A1 (en) * 2015-11-13 2017-05-18 William Marsh Rice University Transition metal free methods of synthesis of biaryl compounds
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
US11026905B2 (en) * 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
JP2023520273A (ja) * 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用

Similar Documents

Publication Publication Date Title
JP2021521243A5 (https=)
IL278112B2 (en) stat3 inhibitors
JP2019518766A5 (https=)
JP2020517616A5 (https=)
JP2023528623A5 (https=)
JP2021500335A5 (https=)
JP2023550122A5 (https=)
CA2545942A1 (en) Aryl imidazoles and their use as anti-cancer agents
IL276575B1 (en) Inhibitors of btk and mutants thereof
JP2007511504A5 (https=)
JP2012505871A5 (https=)
JP2015501782A5 (https=)
JP2013538198A5 (https=)
JP2006508067A5 (https=)
JP2009539848A5 (https=)
JP2024534840A5 (https=)
JP2013536188A5 (https=)
JP2025508272A5 (https=)
JP2011506402A5 (https=)
JP2022533939A5 (https=)
JP2024517498A5 (https=)
JP2020063289A5 (https=)
JP2020521739A5 (https=)
JP2023531970A5 (https=)
JP2013502441A5 (https=)